RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA

被引：0
|
作者：
Lyubov, E. [1 ]
Dzhatdoeva, A. [2 ]
Zhao, Z. [3 ]
Cain, J. [4 ]
机构：
[1] Moscow Inst Psychiat, Moscow, Russia
[2] Janssen Cilag Russia, Moscow, Russia
[3] J&J Worldwide Hlth Econ & Pricing, Raritan, NJ USA
[4] Janssen Pharmaceut, B-2340 Beerse, Belgium
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66903-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A579 / A580
页数：2
相关论文
共 50 条
  • [41] The electronic schizophrenia treatment adherence registry - E-STAR: Data quality assurance gate keeping methods
    Farmer, D
    Ingham, M
    Jacobs, A
    VALUE IN HEALTH, 2005, 8 (03) : 403 - 403
  • [42] The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia
    Chue, Pierre
    Chue, James
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 259 - 269
  • [43] Long term benefits of treatment with risperidone long-acting injection in patients with schizophrenia
    Turner, MS
    Urquhart, E
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S399 - S399
  • [44] Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
    Tim Lambert
    Brett Emmerson
    Harry Hustig
    Sophie Resseler
    An Jacobs
    Belinda Butcher
    BMC Psychiatry, 12
  • [45] Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
    Lambert, Tim
    Emmerson, Brett
    Hustig, Harry
    Resseler, Sophie
    Jacobs, An
    Butcher, Belinda
    BMC PSYCHIATRY, 2012, 12
  • [46] DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE: REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
    Geitona, M.
    Kousoulakou, C.
    Ollandezos, M.
    Papanicolaou, S.
    Athanasakis, K.
    Tsiantou, V
    Kyriopoulos, J.
    VALUE IN HEALTH, 2008, 11 (06) : A345 - A345
  • [47] IMPROVEMENT OF POSITIVE AND NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA, UNDER RISPERIDONE LONG ACTING INJECTION (RLAI) TREATMENT
    Moruzzi, E.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [48] Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone
    Olfson, Mark
    Marcus, Steven C.
    Ascher-Svanum, Haya
    SCHIZOPHRENIA BULLETIN, 2007, 33 (06) : 1379 - 1387
  • [49] Reduction in suicidal ideation and violent behavior after treatment with risperidone long-acting injection from the e-star project in The Netherlands
    van Kooten, M.
    de Weg, H. bij
    de Groot-Stam, E.
    Mulder, C. L.
    Povey, M.
    Manders, M.
    Lam, A.
    Zhao, Z.
    EUROPEAN PSYCHIATRY, 2008, 23 : S127 - S127
  • [50] Long-term treatment of schizophrenia for relapse prevention (LASER): 6-month outcomes in patients started on risperidone long-acting injectable in Germany - Data from the E-star database
    Naber, D
    Mehnert, A
    Rosillon, D
    Farmer, D
    Schreiner, A
    Jacobs, A
    VALUE IN HEALTH, 2005, 8 (06) : A206 - A206
12345